Propeller Health’s digital health tool has received an additional clearance from the U.S. Food and Drug Administration, allowing it to be used to collect data from consumers using AstraZeneca’s Symbicort inhaler. The system is designed to help consumers manage their asthma and chronic obstructive pulmonary disease (COPD).
The system uses sensors to analyze an individual’s inhaler use and sends the data to the company’s Propeller smartphone app, which they can then share with clinicians. The platform was previously cleared to connect to many other inhalers used by individuals with asthma and COPD, including products made by Boehringer Ingelheim, GlaxoSmithKline, Novartis and Orion.
Propeller Health is a leading digital therapeutics company dedicated to the development and commercialization of measurably better medicines. Propeller creates products to more effectively treat disease and improve clinical outcomes for individuals across a range of therapeutic areas through connectivity, analytics, and companion digital experiences. The Propeller platform is used by patients, physicians, and health care organizations in the US, Europe and Asia.
This was reported by FDA News on May 27, 2020.